ENABLING MEANINGFUL METABOLIC DISEASE RESEARCH
Clear efficacy signals are as crucial as keeping research representative and reasonable in this complex field. Worldwide delivers studies that make sense for everyone
LEVERAGING OUR CLINICAL EXPERTISE
Whether your indication has millions of potential participants across the globe or just dozens, know that Worldwide’s dedicated team and global network of trusted partner sites can offer the expertise you need to succeed. Our extensive group of subject matter experts in both rare and common endocrine and metabolic conditions help get studies done right.
RAFAL ZIECINA, MD, PHD
EXECUTIVE DIRECTOR, SCIENTIFIC SOLUTIONS, CARDIOVASCULAR, ENDOCRINE & METABOLIC
With more than 22 years of experience in the World of pharmaceuticals and research, Dr. Ziecina serves as an NAFLD/NASH scientific advisor focused on filing strategies, regulatory and safety strategies. He excels in writing protocols and drug development plans and has extensive experience in study design and medical monitoring for clinical programs.
SHERILYN ADCOCK, RPH, PHD
CHIEF SCIENTIFIC OFFICER, EARLY PHASE DEVELOPMENT
Dr. Adcock has more than 30 years of clinical research experience, much of which has focused on Phase I/II drug development. She has been with Worldwide for 20 years, evaluating scientific, clinical, design and logistical expertise for early clinical development projects. She has also served as Principal or Sub-Investigator on more than 200 clinical trials. Her expertise in pharmacology, bioanalysis and drug development gives every program she works on a competitive edge.
Worldwide offers broad individual and combined team experience across multiple metabolic and liver indications. No matter the size of your study, you get a dedicated, experienced team.
Worldwide is dedicated to maximizing clinical information while minimizing patient discomfort and safety concerns. That’s why our central, bioanalytical, core imaging, and ECG laboratories offer PK/PD and biomarker tests, whole organ volume analysis (liver and spleen), hepatic fat fraction (MRI-PDFF), liver stiffness (MR elastography), SAT/VAT fat depot segmentation, and vibration controlled transient elastography (VCTE) +/- controlled attenuation parameter (CAP).
Worldwide has a large and growing global network of leading investigators, consultants, key opinion leaders, and medical experts in the fields of endocrinology and metabolic health.
Worldwide offers full-service support to metabolic studies from Phase I, starting with our co-located Clinical Pharmacology Unit and Bioanalytical lab, through post-marketing approval.
Human capital that brings clarity to complexity
At Worldwide, we understand that our greatest strength is our personnel—our expert teams around the world that craft unparalleled design and logistics solutions for even the most challenging studies. When you start with a better CRO team, you get a better study experience for the life of your program.
- Acid Sphingomyelinase Deficiency
- (Niemann-Pick Disease) Type C
- Chronic Kidney Disease (Chronic Renal Failure)
- Congenital Adrenal Hyperplasia (Adrenogenital Syndrome)
- Congenital Hyperinsulinemic Hypoglycemia
- Diabetes Type 1
- Diabetes Type 2
- Fabry Disease
- Familial Chylomicronemia (Type I Hyperlipoproteinemia)
- Fatty Acid Biosynthesis Disorders
- Gaucher’s Disease
- Growth Hormone Deficiency
- Insulin-induced Severe Hypoglycemia
- Kidney Disease
- Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease)
- Non-Alcoholic Steatohepatitis (NASH)
- Proteus Syndrome
- Type 1 Diabetes (Juvenile Diabetes)
Our Dedicated Team
Global Head of Regulatory Strategy
Senior Vice President, Project Management, Cardiovascular, Endocrine & Metabolic and Real-World Evidence
Senior Medical Director, Medical Affairs, Cardiovascular, Endocrine & Metabolic
Executive Director, Project Management, NASH
Executive Director, Scientific Solutions, Cardiovascular, Endocrine & Metabolic